Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production1-Reference-Cited by-同舟云学术

Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production1

Published:2002-06 Issue:11 Volume:73 Page:1808-1817
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:Transplantation

Author:

Jiang Hongsi,Wynn Carmen,Pan Fan,Ebbs Aaron,Erickson Laurie M.,Kobayashi Masakazu

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference39 articles.

1. Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996

2. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles

3. New Immunosuppressive Drugs: Mechanistic Insights and Potential Therapeutic Advances

4. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction

5. Distinct Patterns of Cytokine Gene Suppression by the Equivalent Effective Doses of Cyclosporine and Tacrolimus in Rat Heart Allografts

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of two immunosuppressants: tacrolimus and cyclosporine;Journal of the Korean Association of Oral and Maxillofacial Surgeons;2023-12-31

2. Supplementation of Spirulina platensis ethanol extract: influence on mRNA expression and prediction of molecular interactions with IL-10;IOP Conference Series: Earth and Environmental Science;2023-12-01

3. Protective effects of selenium in tacrolimus-induced lung toxicity: potential role of heme oxygenase 1;Canadian Journal of Physiology and Pharmacology;2021-10

4. Szolidszerv-transzplantáció után kialakuló de novo gyulladásos bélbetegség gyermekkorban;Orvosi Hetilap;2021-05-02

5. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis;International Immunopharmacology;2021-05